# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bentrio™ formulation well tolerated in vitro on human nasal epithelium Up to 99% reduction of SARS-CoV-2 viral titer with...
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platform Company to laun...
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T...
Auris Medical Holding Ltd (NASDAQ: EARS) shares are trading higher by 12.7% at $4.16 Thursday morning after the company announc...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitti...